Cameron Shaw

Cameron Shaw
Deakin University · Faculty of Health

MBBS(Hons) FRACP

About

57
Publications
13,083
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,448
Citations
Additional affiliations
January 2010 - present
Deakin University
Position
  • Director of Clinical Studies
February 2007 - present
Geelong Hospital
Position
  • Neurologist

Publications

Publications (57)
Article
Full-text available
Background Adherence and persistence are critical to optimising therapeutic benefit from disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS). This prospective, open-label, multicentre, observational study (AubPRO), conducted in 13 hospital-based neurology clinics around Australia, describes treatment satisfaction in...
Article
Full-text available
Background: Prevention of disability over the long-term is the main treatment goal in multiple sclerosis (MS), however, randomized clinical trials evaluate only short-term treatment effects on disability. This study aimed to define criteria for 6-month confirmed disability progression events of MS with a high probability of resulting in sustained...
Article
Background and Objectives The severity of multiple sclerosis (MS) varies widely among individuals. Understanding the determinants of this heterogeneity will help clinicians optimize the management of MS. The aim of this study was to investigate the association between latitude of residence, ultraviolet B radiation exposure (UVB) and the severity of...
Article
Our inability to reliably predict disease outcomes in multiple sclerosis remains an issue for clinicians and clinical trialists. This study aims to create, from available clinical, genetic, and environmental factors; a clinical-environmental-genotypic prognostic index to predict the probability of new relapses and disability worsening. The analyses...
Conference Paper
Background Because of methodological challenges comparisons of multiple treatments in multiple sclerosis cohorts have been limited to pairwise and triple comparisons. Objectives Extend marginal structural models (MSM) to allow simultaneous comparisons of multiple MS treatments. Methods We selected patients from the MSBase registry with Clinically...
Article
Objective To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis, we modelled disability outcomes in 14,717 patients. Methods We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year and exposed to a multiple sclerosis therapy, and a subset of patients with ≥...
Article
Background Dietary patterns and their association with subsequent clinical course have not been well studied in early multiple sclerosis (MS). Objectives To describe dietary patterns in people in 5 years following first clinical demyelination and assess associations with MS conversion and relapse. Methods This study included baseline food frequen...
Article
Full-text available
Background/objective Observational clinical data from cladribine-treated patients with relapsing forms of multiple sclerosis (MS) were recorded in the Australian MS registry powered by the MSBase registry platform (5-year follow-up) and analysed to complement information from the pivotal cladribine clinical trials in MS. Methods A cohort of 90 cla...
Article
Full-text available
Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) show overlap in their clinical features. We performed an analysis of relapses with the aim of determining differences between the two conditions. Cases of NMOSD and age- and sex-matched MS controls were collected from across Australia and New Zealand. Demographic and clinic...
Article
Full-text available
Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and New Zealand populations with the aim of characterising the clinical features and establishing the value of recently revised diagnostic...
Article
Background The Multiple Sclerosis Severity Score (MSSS) is a widely used measure of the disability progression rate. However, the global MSSS may not be the best basis for comparison between all patient groups. Objective We evaluated sex-specific and onset phenotype–specific MSSS matrices to determine if they were more effective than the global MS...
Preprint
Full-text available
Objective Whether immunotherapy improves long-term disability in multiple sclerosis has not been satisfactorily demonstrated. This study examined the effect of immunotherapy on long-term disability outcomes in relapsing-remitting multiple sclerosis. Methods We studied patients from MSBase followed for ≥1 year, with ≥3 visits, ≥1 visit per year and...
Article
Background The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective The aim of this study was to determine the demographic, clinical and paraclinical features that influence the risk of conversion to secondary progressive multiple sclerosis. Methods Patients with adult...
Article
Background: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RRMS) may be increasing. Objective: To retrospectively determine incidence of pregnancy, DMT exposure and pregnancy outcomes in women with RRMS. Methods: We identified all women with RRMS aged 15-45 years in the MSBase Registry...
Article
Full-text available
Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon β, fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, exposure to the study therapies and ⩾1-year on-treatment follow-up from MSBase. Three pairwise propensity score-matched ana...
Conference Paper
OBJECTIVES: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. BACKGROUND: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and p...
Article
Full-text available
Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence an...
Article
Background Age at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what factors can influence AAO may shed light on the aetiology of this complex disease, and have applications in the diagnostic process. Methods The study cohort of 22 162 eligible patients from 21...
Article
Full-text available
A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definitio...
Article
Objective: This study evaluated the effect of relapse phenotype on disability accumulation in multiple sclerosis. Methods: Analysis of prospectively collected data was conducted in 19,504 patients with relapse-onset multiple sclerosis and minimum 1-year prospective follow-up from the MSBase cohort study. Multivariable linear regression models as...
Article
Background: Anxiety and depression are common in multiple sclerosis (MS). We evaluated the prevalence and factors associated with anxiety, depression and fatigue at the 5-year review of a longitudinal cohort study following a first clinical diagnosis of CNS demyelination (FCD). Methods: Cases with a FCD were recruited soon after diagnosis and fo...
Article
Full-text available
Introduction: Leptomeningeal rheumatoid nodules are a rare condition. This case demonstrates the unique presentation and diagnostic workup for the distinctive condition and highlights the difficulties surrounding therapeutics. Case Presentation: A 67 year old woman presented with recurrent transient ischaemic attack-like episodes over a 2 year peri...
Article
Full-text available
Limited data suggest that multiple sclerosis (MS) in Latin America (LA) could be less severe than in the rest of the world. The objective was to compare the course of MS between LA and other regions. Methods Centers from 18 countries with >20 cases enrolled in the MSBase Registry participated. Patients with MS with a disease duration of >1 year an...
Article
Full-text available
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system with a multifactorial aetiology and highly variable natural history. A growing understanding of the immunopathogenesis of the condition has led to an expanding array of therapies for this previously untreatable disease. While a cure for MS remains elusive, the potential...
Article
Full-text available
Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and para...
Article
Full-text available
Objective: To assess demographic, clinical, magnetic resonance imaging, and treatment exposure predictors of time to 3 or 12-month confirmed disability worsening in clinically isolated syndrome (CIS) and early multiple sclerosis (MS). Methods: We utilized the MSBase Incident Study (MSBasis), a prospective cohort study of outcome after CIS. Predict...
Article
A 67-year-old woman presented with recurrent transient ischaemic attack-like episodes over a 2 year period. Nodular enhancing leptomeningeal changes were detected on MRI and were consistent with meningeal rheumatoid nodules on biopsy. The patient’s nodular disease continued to progress and regress clinically and radiologically irrespective of disea...
Article
Objective: Previous studies assessing seasonal variation of relapse onset in multiple sclerosis have had conflicting results. Small relapse numbers, differing diagnostic criteria and single region studies limit the generalizability of prior results. The aim of this study was to determine if there is a temporal variation in onset of relapses in both...
Conference Paper
Full-text available
Background: Confirmed progression of disability is an outcome traditionally used by the trials studying the effect of disease modifying therapy in multiple sclerosis (MS). Given that various definitions of confirmed disability progression are being used, a comprehensive evaluation of their performance in a large population representative of clinica...
Article
The aim was to analyse risk of relapse phenotype recurrence in multiple sclerosis and to characterise the effect of demographic and clinical features on this phenotype. Information about relapses was collected using MSBase, an international observational registry. Associations between relapse phenotypes and history of similar relapses or patient ch...
Article
OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse on fingolimod. METHODS: Data were obtained from the MSBas...
Article
In Part 2 of this three part review of multiple sclerosis (MS) treatment with a particular focus on the Australian and New Zealand perspective, we review the newer therapies that have recently become available and emerging therapies that have now completed phase III clinical trial programs. We go on to compare the relative efficacies of these newer...
Article
In this third and final part of our review of multiple sclerosis (MS) treatment we look at the practical day-to-day management issues that are likely to influence individual treatment decisions. Whilst efficacy is clearly of considerable importance, tolerability and the potential for adverse effects often play a significant role in informing indivi...
Article
Multiple sclerosis (MS) is a potentially life-changing immune mediated disease of the central nervous system. Until recently, treatment has been largely confined to acute treatment of relapses, symptomatic therapies and rehabilitation. Through persistent efforts of dedicated physicians and scientists around the globe for 160 years, a number of ther...
Article
The aim of this work was to evaluate sex differences in the incidence of multiple sclerosis relapses; assess the relationship between sex and primary progressive disease course; and compare effects of age and disease duration on relapse incidence. Annualized relapse rates were calculated using the MSBase registry. Patients with incomplete data or <...
Article
Full-text available
Several studies have shown that pregnancy reduces multiple sclerosis (MS) relapses, which increase in the early postpartum period. Postpartum relapse risk has been predicted by pre-pregnancy disease activity in some studies. To re-examine effect of pregnancy on relapses using the large international MSBase Registry, examining predictors of early po...
Conference Paper
Background: Recent published case studies have described severe disease reactivation or rebound occurring shortly after fingolimod (FTY) initiation in patients previously treated with natalizumab (NAT). Objectives: To compare relapse activity and predictors of first relapse post-FTY initiation in a) patients switching from NAT to pre-switch relap...
Conference Paper
Introduction: Our knowledge of incidence and outcomes of MS relapses with specific symptomatology is limited. For example, optic neuritis is more common in early MS and the ability to recover deteriorates with longer disease duration. However, a comprehensive evaluation of multiple sclerosis relapse phenotypes, comprising clinical presentations, se...
Conference Paper
Introduction: Only one large retrospective cohort study and several smaller analyses examined predictors of relapse incidence in MS. Sex, age and MS duration were suggested as determinants of relapse activity. While in relapsing-remitting MS women are overrepresented in the ratio of 3:1 to men, in primary progressive disease both sexes are represen...
Conference Paper
Background: The first 12-month confirmed disability progression event after clinically isolated syndrome (CIS) onset likely reflects persistent MS-related disability. Predictors of long-term sustained disability progression at CIS onset are not well characterised in real world datasets, and potential treatment effects are uncertain. Objective: We...
Article
Full-text available
Objectives: To compare treatment persistence between two dosages of interferon β-1a in a large observational multiple sclerosis registry and assess disease outcomes of first line MS treatment at these dosages using propensity scoring to adjust for baseline imbalance in disease characteristics. Methods: Treatment discontinuations were evaluated i...
Data
Assignation to treatment dosage by treating centres. The table shows number of patients assigned to either Rebif dosage at each of the participating centres. Odds relative to the reference centre (IT-002) of assignation to the higher dosage are given. The results were incorporated in the individual propensity scores. (DOCX)
Article
Full-text available
To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population. Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisation, persistence, predictors of treatment discontinuation and switch ra...
Data
Predictors of first treatment discontinuation. Table reports univariable and multivariable Cox proportional hazards regression analysis. Comparator group: GA-treated patients. (DOCX)
Data
Predictors of subsequent treatment discontinuation. Table reports univariable and multivariable Cox proportional hazards regression analysis. Comparator group: NAT-treated patients. (DOCX)
Article
Background: Patients with multiple sclerosis (MS) are more frequently born in spring when compared to autumn. Fluctuation of UV-light has been hypothesized to drive this phenomenon. Aim: To assess the correlation between fluctuation of sunlight and birth season in persons with MS. Methods: For this record-linkage study, we collected from the i...
Conference Paper
Background Pregnancy counselling is an important aspect of the care of women of childbearing age who have multiple sclerosis (MS). The issue of cessation of interferon therapy for conception and pregnancy still provokes debate within the MS community, given conflicting study findings. Here we present a review of the literature. Methods A literature...
Article
Full-text available
With the advent of MRI scanning, the value of lumbar puncture to assess oligoclonal band (OCB) status-for the diagnosis of multiple sclerosis (MS) is increasingly uncertain. One major issue is that the reported frequency of cerebrospinal fluid (CSF)-restricted oligoclonal banding for the diagnosis of MS varies considerably in different studies. In...
Article
The task of confirming a diagnosis of multiple sclerosis (MS), one of the commonest neurological disorders affecting young adults, has altered significantly in the magnetic resonance imaging era. Conversely, key principles, most notably objective documentation of neurological dissemination in time and space, remain fundamental to the process. Clini...

Network

Cited By

Projects

Project (1)
Project
Identify clinical, paraclinical and environmental predictors of long-term outcomes of people with MS using MSBase-derived data